More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$12.12B
EPS
3.94
P/E ratio
10.8
Price to sales
0.52
Dividend yield
4.018%
Beta
0.792192
Previous close
$21.86
Today's open
$21.78
Day's range
$21.69 - $21.94
52 week range
$20.02 - $26.42
show more
CEO
Shervin J. Korangy
Employees
106291
Headquarters
Bad Homburg,
Exchange
New York Stock Exchange
Shares outstanding
558577770
Issue type
American Depository Receipt
Healthcare
Healthcare Providers & Services
Dialysis Giants DaVita and Fresenius Blocking Competition In Washington, Lawsuit Accuses
Washington Attorney General Nick Brown on Tuesday filed a lawsuit accusing the state's two largest for-profit dialysis providers of imposing illegal noncompete agreements on medical directors, blocking competition and reducing care options for kidney failure patients.
Benzinga • Nov 12, 2026

What Fresenius Medical Care AG & Co. KGaA (FMS) Said on Its Q3 Earnings Call
Fresenius Medical Care AG & Co. KGaA NYSE: FMS reported broadly stable third-quarter revenue and a decline in operating income as reimbursement pressures and inflation weighed on results, while the company continued to advance its U.S. rollout of high-volume hemodiafiltration technology and execute its share repurchase program.
MarketBeat • Nov 4, 2026

Fresenius raises 2026 outlook for second time after strong Q3
Healthcare group Fresenius lifted its full-year expectations on Wednesday after reporting higher-than-anticipated third-quarter results, as strong performance at the Kabi and Helios divisions supported earnings.
Reuters • Nov 4, 2026

Fresenius Medical cuts top end of 2026 profit outlook
German dialysis specialist Fresenius Medical Care cut the upper end of its 2026 operating income outlook on Tuesday after US treatment volumes declined for a third consecutive quarter, as regulatory and inflation headwinds weighed on quarterly earnings.
Reuters • Nov 3, 2026

Fresenius Medical Care AG (FMS) Q3 2026 Earnings Call Transcript
Fresenius Medical Care AG (FMS) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 3, 2026

Fresenius Medical Care reports third quarter 2026 performance partially offsetting headwinds and narrowing full year outlook
Stable organic revenue1 development driven by growth in Care Delivery and Care Enablement, offset by the expected decline in profit-neutral Value-Based Care Operating income2 decreased by 6%, due to regulatory and inflation headwinds Reported operating income decreased by 19% and reported net income3 decreased by 42%, mainly due to one-time costs related to the China strategy refinement Earnings per share2 (EPS) remained stable supported by the share buyback program 348 U.S. clinics representing 16% of our U.S. dialysis machines converted to the 5008X CAREsystem™ with 1.3 million treatments4 FY 2026 outlook – revenue outlook broadly flat, operating income outlook narrowed to between flat and a negative mid-single digit percent growth rate BAD HOMBURG, Germany, Nov. 3, 2026 /PRNewswire/ -- "Three weeks into my role as CEO, I am energized by the opportunities ahead. As a global leader in kidney care, Fresenius Medical Care combines exceptional capabilities with unparalleled reach.
PRNewsWire • Nov 3, 2026

FMS Launches multiFiltratePRO System for U.S. Patients With Acute AKI
Fresenius Medical Care launches multiFiltratePRO kidney therapy system in the United States, expanding critical care options and growth opportunities.
Zacks Investment Research • Oct 23, 2026

Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™
Expands access to Fresenius Medical Care's globally established portfolio of advanced kidney replacement therapies in the U.S. FDA clearance of multiFiltratePRO and approval of dedicated solutions expand continuous kidney replacement therapy options for U.S. patients requiring treatment for acute kidney injury Integrated technology helps hospital intensive care teams deliver complex treatment simply and efficiently BAD HOMBURG, Germany, Oct. 21, 2026 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for people with kidney disease, today announced the U.S. launch of the multiFiltratePRO System for critically ill patients with acute kidney injury (AKI). multiFiltratePRO's integrated technology eliminates the need for separate citrate and calcium pumps, and automatically adjusts as treatment conditions change, making complex treatment easier for hospital intensive care teams to manage.
PRNewsWire • Oct 21, 2026

Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026
BAD HOMBURG, Germany, Oct. 19, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, presents new research and evidence-driven innovations aimed at improving patient outcomes during the American Society of Nephrology's (ASN) Kidney Week 2026, taking place October 21-25 in Denver, Colorado.
PRNewsWire • Oct 19, 2026

Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
FMS' transformation is lifting profitability, while HDF, value-based care and cost savings offset volume and reimbursement pressures.
Zacks Investment Research • Oct 7, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an) commission-free¹. Build wealth for the long term using automated trading and transfers.